0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Neurofibromatosis Type 1 Market Insights and Forecast to 2028
Published Date: January 2022
|
Report Code: QYRE-Auto-23X8187
Home | Market Reports | Health | Health Conditions | Genetic Disorders
Global Neurofibromatosis Type 1 Market Insights and Forecast to 2028

Global Neurofibromatosis Type 1 Market Insights and Forecast to 2028

Code: QYRE-Auto-23X8187
Report
January 2022
76 Pages
QYResearch
Region: Global,
Description
Table of Content
Tables & Figures
NF1 is a debilitating genetic condition that affects one in every 3,000 to 4,000 individuals. It is caused by a spontaneous or inherited mutation in the NF1 gene and is associated with many symptoms, including soft lumps on and under the skin (cutaneous neurofibromas) and skin pigmentation (so-called ‘café au lait’ spots) and, in 30-50% of patients, tumours develop on the nerve sheaths (plexiform neurofibromas). 
Market Analysis and Insights: Global Neurofibromatosis Type 1 Market

Due to the COVID-19 pandemic, the global Neurofibromatosis Type 1 market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period.

Fully considering the economic change by this health crisis, 10 mg accounting for % of the Neurofibromatosis Type 1 global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period.

While Hospitals segment is altered to an % CAGR throughout this forecast period.
China Neurofibromatosis Type 1 market size is valued at US$ million in 2021, while the US and Europe Neurofibromatosis Type 1 are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period.

As for the Europe Neurofibromatosis Type 1 landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.

The global key manufacturers of Neurofibromatosis Type 1 include AstraZeneca and Merck etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Neurofibromatosis Type 1 Scope and Segment
Neurofibromatosis Type 1 market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Neurofibromatosis Type 1 market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.

Segment by Type

10 mg
25 mg

Segment by Application

Hospitals
Clinics
Others

BY COMPANY

AstraZeneca
Merck

BY REGION

North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
1 Study Coverage
1.1 Neurofibromatosis Type 1 Product Introduction
1.2 Market by Type
1.2.1 Global Neurofibromatosis Type 1 Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 10 mg
1.2.3 25 mg
1.3 Market by Application
1.3.1 Global Neurofibromatosis Type 1 Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Neurofibromatosis Type 1 Sales Estimates and Forecasts 2017-2028
2.2 Global Neurofibromatosis Type 1 Revenue Estimates and Forecasts 2017-2028
2.3 Global Neurofibromatosis Type 1 Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Neurofibromatosis Type 1 Sales by Region
2.4.1 Global Neurofibromatosis Type 1 Sales by Region (2017-2022)
2.4.2 Global Sales Neurofibromatosis Type 1 by Region (2023-2028)
2.5 Global Neurofibromatosis Type 1 Revenue by Region
2.5.1 Global Neurofibromatosis Type 1 Revenue by Region (2017-2022)
2.5.2 Global Neurofibromatosis Type 1 Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Neurofibromatosis Type 1 Sales by Manufacturers
3.1.1 Global Top Neurofibromatosis Type 1 Manufacturers by Sales (2017-2022)
3.1.2 Global Neurofibromatosis Type 1 Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Neurofibromatosis Type 1 in 2021
3.2 Global Neurofibromatosis Type 1 Revenue by Manufacturers
3.2.1 Global Neurofibromatosis Type 1 Revenue by Manufacturers (2017-2022)
3.2.2 Global Neurofibromatosis Type 1 Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Neurofibromatosis Type 1 Revenue in 2021
3.3 Global Neurofibromatosis Type 1 Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Neurofibromatosis Type 1 Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Neurofibromatosis Type 1 Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Neurofibromatosis Type 1 Sales by Type
4.1.1 Global Neurofibromatosis Type 1 Historical Sales by Type (2017-2022)
4.1.2 Global Neurofibromatosis Type 1 Forecasted Sales by Type (2023-2028)
4.1.3 Global Neurofibromatosis Type 1 Sales Market Share by Type (2017-2028)
4.2 Global Neurofibromatosis Type 1 Revenue by Type
4.2.1 Global Neurofibromatosis Type 1 Historical Revenue by Type (2017-2022)
4.2.2 Global Neurofibromatosis Type 1 Forecasted Revenue by Type (2023-2028)
4.2.3 Global Neurofibromatosis Type 1 Revenue Market Share by Type (2017-2028)
4.3 Global Neurofibromatosis Type 1 Price by Type
4.3.1 Global Neurofibromatosis Type 1 Price by Type (2017-2022)
4.3.2 Global Neurofibromatosis Type 1 Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Neurofibromatosis Type 1 Sales by Application
5.1.1 Global Neurofibromatosis Type 1 Historical Sales by Application (2017-2022)
5.1.2 Global Neurofibromatosis Type 1 Forecasted Sales by Application (2023-2028)
5.1.3 Global Neurofibromatosis Type 1 Sales Market Share by Application (2017-2028)
5.2 Global Neurofibromatosis Type 1 Revenue by Application
5.2.1 Global Neurofibromatosis Type 1 Historical Revenue by Application (2017-2022)
5.2.2 Global Neurofibromatosis Type 1 Forecasted Revenue by Application (2023-2028)
5.2.3 Global Neurofibromatosis Type 1 Revenue Market Share by Application (2017-2028)
5.3 Global Neurofibromatosis Type 1 Price by Application
5.3.1 Global Neurofibromatosis Type 1 Price by Application (2017-2022)
5.3.2 Global Neurofibromatosis Type 1 Price Forecast by Application (2023-2028)
6 North America
6.1 North America Neurofibromatosis Type 1 Market Size by Type
6.1.1 North America Neurofibromatosis Type 1 Sales by Type (2017-2028)
6.1.2 North America Neurofibromatosis Type 1 Revenue by Type (2017-2028)
6.2 North America Neurofibromatosis Type 1 Market Size by Application
6.2.1 North America Neurofibromatosis Type 1 Sales by Application (2017-2028)
6.2.2 North America Neurofibromatosis Type 1 Revenue by Application (2017-2028)
6.3 North America Neurofibromatosis Type 1 Market Size by Country
6.3.1 North America Neurofibromatosis Type 1 Sales by Country (2017-2028)
6.3.2 North America Neurofibromatosis Type 1 Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Neurofibromatosis Type 1 Market Size by Type
7.1.1 Europe Neurofibromatosis Type 1 Sales by Type (2017-2028)
7.1.2 Europe Neurofibromatosis Type 1 Revenue by Type (2017-2028)
7.2 Europe Neurofibromatosis Type 1 Market Size by Application
7.2.1 Europe Neurofibromatosis Type 1 Sales by Application (2017-2028)
7.2.2 Europe Neurofibromatosis Type 1 Revenue by Application (2017-2028)
7.3 Europe Neurofibromatosis Type 1 Market Size by Country
7.3.1 Europe Neurofibromatosis Type 1 Sales by Country (2017-2028)
7.3.2 Europe Neurofibromatosis Type 1 Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Neurofibromatosis Type 1 Market Size by Type
8.1.1 Asia Pacific Neurofibromatosis Type 1 Sales by Type (2017-2028)
8.1.2 Asia Pacific Neurofibromatosis Type 1 Revenue by Type (2017-2028)
8.2 Asia Pacific Neurofibromatosis Type 1 Market Size by Application
8.2.1 Asia Pacific Neurofibromatosis Type 1 Sales by Application (2017-2028)
8.2.2 Asia Pacific Neurofibromatosis Type 1 Revenue by Application (2017-2028)
8.3 Asia Pacific Neurofibromatosis Type 1 Market Size by Region
8.3.1 Asia Pacific Neurofibromatosis Type 1 Sales by Region (2017-2028)
8.3.2 Asia Pacific Neurofibromatosis Type 1 Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Neurofibromatosis Type 1 Market Size by Type
9.1.1 Latin America Neurofibromatosis Type 1 Sales by Type (2017-2028)
9.1.2 Latin America Neurofibromatosis Type 1 Revenue by Type (2017-2028)
9.2 Latin America Neurofibromatosis Type 1 Market Size by Application
9.2.1 Latin America Neurofibromatosis Type 1 Sales by Application (2017-2028)
9.2.2 Latin America Neurofibromatosis Type 1 Revenue by Application (2017-2028)
9.3 Latin America Neurofibromatosis Type 1 Market Size by Country
9.3.1 Latin America Neurofibromatosis Type 1 Sales by Country (2017-2028)
9.3.2 Latin America Neurofibromatosis Type 1 Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Neurofibromatosis Type 1 Market Size by Type
10.1.1 Middle East and Africa Neurofibromatosis Type 1 Sales by Type (2017-2028)
10.1.2 Middle East and Africa Neurofibromatosis Type 1 Revenue by Type (2017-2028)
10.2 Middle East and Africa Neurofibromatosis Type 1 Market Size by Application
10.2.1 Middle East and Africa Neurofibromatosis Type 1 Sales by Application (2017-2028)
10.2.2 Middle East and Africa Neurofibromatosis Type 1 Revenue by Application (2017-2028)
10.3 Middle East and Africa Neurofibromatosis Type 1 Market Size by Country
10.3.1 Middle East and Africa Neurofibromatosis Type 1 Sales by Country (2017-2028)
10.3.2 Middle East and Africa Neurofibromatosis Type 1 Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Corporation Information
11.1.2 AstraZeneca Overview
11.1.3 AstraZeneca Neurofibromatosis Type 1 Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 AstraZeneca Neurofibromatosis Type 1 Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 AstraZeneca Recent Developments
11.2 Merck
11.2.1 Merck Corporation Information
11.2.2 Merck Overview
11.2.3 Merck Neurofibromatosis Type 1 Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Merck Neurofibromatosis Type 1 Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Merck Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Neurofibromatosis Type 1 Industry Chain Analysis
12.2 Neurofibromatosis Type 1 Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Neurofibromatosis Type 1 Production Mode & Process
12.4 Neurofibromatosis Type 1 Sales and Marketing
12.4.1 Neurofibromatosis Type 1 Sales Channels
12.4.2 Neurofibromatosis Type 1 Distributors
12.5 Neurofibromatosis Type 1 Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Neurofibromatosis Type 1 Industry Trends
13.2 Neurofibromatosis Type 1 Market Drivers
13.3 Neurofibromatosis Type 1 Market Challenges
13.4 Neurofibromatosis Type 1 Market Restraints
14 Key Findings in The Global Neurofibromatosis Type 1 Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
    Table 1. Global Neurofibromatosis Type 1 Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
    Table 2. Major Manufacturers of 10 mg
    Table 3. Major Manufacturers of 25 mg
    Table 4. Global Neurofibromatosis Type 1 Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
    Table 5. Global Neurofibromatosis Type 1 Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
    Table 6. Global Neurofibromatosis Type 1 Sales by Region (2017-2022) & (K Units)
    Table 7. Global Neurofibromatosis Type 1 Sales Market Share by Region (2017-2022)
    Table 8. Global Neurofibromatosis Type 1 Sales by Region (2023-2028) & (K Units)
    Table 9. Global Neurofibromatosis Type 1 Sales Market Share by Region (2023-2028)
    Table 10. Global Neurofibromatosis Type 1 Revenue by Region (2017-2022) & (US$ Million)
    Table 11. Global Neurofibromatosis Type 1 Revenue Market Share by Region (2017-2022)
    Table 12. Global Neurofibromatosis Type 1 Revenue by Region (2023-2028) & (US$ Million)
    Table 13. Global Neurofibromatosis Type 1 Revenue Market Share by Region (2023-2028)
    Table 14. Global Neurofibromatosis Type 1 Sales by Manufacturers (2017-2022) & (K Units)
    Table 15. Global Neurofibromatosis Type 1 Sales Share by Manufacturers (2017-2022)
    Table 16. Global Neurofibromatosis Type 1 Revenue by Manufacturers (2017-2022) & (US$ Million)
    Table 17. Global Neurofibromatosis Type 1 Revenue Share by Manufacturers (2017-2022)
    Table 18. Neurofibromatosis Type 1 Price by Manufacturers (2017-2022) &(US$/Unit)
    Table 19. Global Neurofibromatosis Type 1 Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 20. Global Neurofibromatosis Type 1 by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurofibromatosis Type 1 as of 2021)
    Table 21. Neurofibromatosis Type 1 Manufacturing Base Distribution and Headquarters
    Table 22. Manufacturers Neurofibromatosis Type 1 Product Offered
    Table 23. Date of Manufacturers Enter into Neurofibromatosis Type 1 Market
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Neurofibromatosis Type 1 Sales by Type (2017-2022) & (K Units)
    Table 26. Global Neurofibromatosis Type 1 Sales by Type (2023-2028) & (K Units)
    Table 27. Global Neurofibromatosis Type 1 Sales Share by Type (2017-2022)
    Table 28. Global Neurofibromatosis Type 1 Sales Share by Type (2023-2028)
    Table 29. Global Neurofibromatosis Type 1 Revenue by Type (2017-2022) & (US$ Million)
    Table 30. Global Neurofibromatosis Type 1 Revenue by Type (2023-2028) & (US$ Million)
    Table 31. Global Neurofibromatosis Type 1 Revenue Share by Type (2017-2022)
    Table 32. Global Neurofibromatosis Type 1 Revenue Share by Type (2023-2028)
    Table 33. Neurofibromatosis Type 1 Price by Type (2017-2022) & (US$/Unit)
    Table 34. Global Neurofibromatosis Type 1 Price Forecast by Type (2023-2028) & (US$/Unit)
    Table 35. Global Neurofibromatosis Type 1 Sales by Application (2017-2022) & (K Units)
    Table 36. Global Neurofibromatosis Type 1 Sales by Application (2023-2028) & (K Units)
    Table 37. Global Neurofibromatosis Type 1 Sales Share by Application (2017-2022)
    Table 38. Global Neurofibromatosis Type 1 Sales Share by Application (2023-2028)
    Table 39. Global Neurofibromatosis Type 1 Revenue by Application (2017-2022) & (US$ Million)
    Table 40. Global Neurofibromatosis Type 1 Revenue by Application (2023-2028) & (US$ Million)
    Table 41. Global Neurofibromatosis Type 1 Revenue Share by Application (2017-2022)
    Table 42. Global Neurofibromatosis Type 1 Revenue Share by Application (2023-2028)
    Table 43. Neurofibromatosis Type 1 Price by Application (2017-2022) & (US$/Unit)
    Table 44. Global Neurofibromatosis Type 1 Price Forecast by Application (2023-2028) & (US$/Unit)
    Table 45. North America Neurofibromatosis Type 1 Sales by Type (2017-2022) & (K Units)
    Table 46. North America Neurofibromatosis Type 1 Sales by Type (2023-2028) & (K Units)
    Table 47. North America Neurofibromatosis Type 1 Revenue by Type (2017-2022) & (US$ Million)
    Table 48. North America Neurofibromatosis Type 1 Revenue by Type (2023-2028) & (US$ Million)
    Table 49. North America Neurofibromatosis Type 1 Sales by Application (2017-2022) & (K Units)
    Table 50. North America Neurofibromatosis Type 1 Sales by Application (2023-2028) & (K Units)
    Table 51. North America Neurofibromatosis Type 1 Revenue by Application (2017-2022) & (US$ Million)
    Table 52. North America Neurofibromatosis Type 1 Revenue by Application (2023-2028) & (US$ Million)
    Table 53. North America Neurofibromatosis Type 1 Sales by Country (2017-2022) & (K Units)
    Table 54. North America Neurofibromatosis Type 1 Sales by Country (2023-2028) & (K Units)
    Table 55. North America Neurofibromatosis Type 1 Revenue by Country (2017-2022) & (US$ Million)
    Table 56. North America Neurofibromatosis Type 1 Revenue by Country (2023-2028) & (US$ Million)
    Table 57. Europe Neurofibromatosis Type 1 Sales by Type (2017-2022) & (K Units)
    Table 58. Europe Neurofibromatosis Type 1 Sales by Type (2023-2028) & (K Units)
    Table 59. Europe Neurofibromatosis Type 1 Revenue by Type (2017-2022) & (US$ Million)
    Table 60. Europe Neurofibromatosis Type 1 Revenue by Type (2023-2028) & (US$ Million)
    Table 61. Europe Neurofibromatosis Type 1 Sales by Application (2017-2022) & (K Units)
    Table 62. Europe Neurofibromatosis Type 1 Sales by Application (2023-2028) & (K Units)
    Table 63. Europe Neurofibromatosis Type 1 Revenue by Application (2017-2022) & (US$ Million)
    Table 64. Europe Neurofibromatosis Type 1 Revenue by Application (2023-2028) & (US$ Million)
    Table 65. Europe Neurofibromatosis Type 1 Sales by Country (2017-2022) & (K Units)
    Table 66. Europe Neurofibromatosis Type 1 Sales by Country (2023-2028) & (K Units)
    Table 67. Europe Neurofibromatosis Type 1 Revenue by Country (2017-2022) & (US$ Million)
    Table 68. Europe Neurofibromatosis Type 1 Revenue by Country (2023-2028) & (US$ Million)
    Table 69. Asia Pacific Neurofibromatosis Type 1 Sales by Type (2017-2022) & (K Units)
    Table 70. Asia Pacific Neurofibromatosis Type 1 Sales by Type (2023-2028) & (K Units)
    Table 71. Asia Pacific Neurofibromatosis Type 1 Revenue by Type (2017-2022) & (US$ Million)
    Table 72. Asia Pacific Neurofibromatosis Type 1 Revenue by Type (2023-2028) & (US$ Million)
    Table 73. Asia Pacific Neurofibromatosis Type 1 Sales by Application (2017-2022) & (K Units)
    Table 74. Asia Pacific Neurofibromatosis Type 1 Sales by Application (2023-2028) & (K Units)
    Table 75. Asia Pacific Neurofibromatosis Type 1 Revenue by Application (2017-2022) & (US$ Million)
    Table 76. Asia Pacific Neurofibromatosis Type 1 Revenue by Application (2023-2028) & (US$ Million)
    Table 77. Asia Pacific Neurofibromatosis Type 1 Sales by Region (2017-2022) & (K Units)
    Table 78. Asia Pacific Neurofibromatosis Type 1 Sales by Region (2023-2028) & (K Units)
    Table 79. Asia Pacific Neurofibromatosis Type 1 Revenue by Region (2017-2022) & (US$ Million)
    Table 80. Asia Pacific Neurofibromatosis Type 1 Revenue by Region (2023-2028) & (US$ Million)
    Table 81. Latin America Neurofibromatosis Type 1 Sales by Type (2017-2022) & (K Units)
    Table 82. Latin America Neurofibromatosis Type 1 Sales by Type (2023-2028) & (K Units)
    Table 83. Latin America Neurofibromatosis Type 1 Revenue by Type (2017-2022) & (US$ Million)
    Table 84. Latin America Neurofibromatosis Type 1 Revenue by Type (2023-2028) & (US$ Million)
    Table 85. Latin America Neurofibromatosis Type 1 Sales by Application (2017-2022) & (K Units)
    Table 86. Latin America Neurofibromatosis Type 1 Sales by Application (2023-2028) & (K Units)
    Table 87. Latin America Neurofibromatosis Type 1 Revenue by Application (2017-2022) & (US$ Million)
    Table 88. Latin America Neurofibromatosis Type 1 Revenue by Application (2023-2028) & (US$ Million)
    Table 89. Latin America Neurofibromatosis Type 1 Sales by Country (2017-2022) & (K Units)
    Table 90. Latin America Neurofibromatosis Type 1 Sales by Country (2023-2028) & (K Units)
    Table 91. Latin America Neurofibromatosis Type 1 Revenue by Country (2017-2022) & (US$ Million)
    Table 92. Latin America Neurofibromatosis Type 1 Revenue by Country (2023-2028) & (US$ Million)
    Table 93. Middle East and Africa Neurofibromatosis Type 1 Sales by Type (2017-2022) & (K Units)
    Table 94. Middle East and Africa Neurofibromatosis Type 1 Sales by Type (2023-2028) & (K Units)
    Table 95. Middle East and Africa Neurofibromatosis Type 1 Revenue by Type (2017-2022) & (US$ Million)
    Table 96. Middle East and Africa Neurofibromatosis Type 1 Revenue by Type (2023-2028) & (US$ Million)
    Table 97. Middle East and Africa Neurofibromatosis Type 1 Sales by Application (2017-2022) & (K Units)
    Table 98. Middle East and Africa Neurofibromatosis Type 1 Sales by Application (2023-2028) & (K Units)
    Table 99. Middle East and Africa Neurofibromatosis Type 1 Revenue by Application (2017-2022) & (US$ Million)
    Table 100. Middle East and Africa Neurofibromatosis Type 1 Revenue by Application (2023-2028) & (US$ Million)
    Table 101. Middle East and Africa Neurofibromatosis Type 1 Sales by Country (2017-2022) & (K Units)
    Table 102. Middle East and Africa Neurofibromatosis Type 1 Sales by Country (2023-2028) & (K Units)
    Table 103. Middle East and Africa Neurofibromatosis Type 1 Revenue by Country (2017-2022) & (US$ Million)
    Table 104. Middle East and Africa Neurofibromatosis Type 1 Revenue by Country (2023-2028) & (US$ Million)
    Table 105. AstraZeneca Corporation Information
    Table 106. AstraZeneca Description and Major Businesses
    Table 107. AstraZeneca Neurofibromatosis Type 1 Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 108. AstraZeneca Neurofibromatosis Type 1 Product Model Numbers, Pictures, Descriptions and Specifications
    Table 109. AstraZeneca Recent Developments
    Table 110. Merck Corporation Information
    Table 111. Merck Description and Major Businesses
    Table 112. Merck Neurofibromatosis Type 1 Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
    Table 113. Merck Neurofibromatosis Type 1 Product Model Numbers, Pictures, Descriptions and Specifications
    Table 114. Merck Recent Developments
    Table 115. Key Raw Materials Lists
    Table 116. Raw Materials Key Suppliers Lists
    Table 117. Neurofibromatosis Type 1 Distributors List
    Table 118. Neurofibromatosis Type 1 Customers List
    Table 119. Neurofibromatosis Type 1 Market Trends
    Table 120. Neurofibromatosis Type 1 Market Drivers
    Table 121. Neurofibromatosis Type 1 Market Challenges
    Table 122. Neurofibromatosis Type 1 Market Restraints
    Table 123. Research Programs/Design for This Report
    Table 124. Key Data Information from Secondary Sources
    Table 125. Key Data Information from Primary Sources
List of Figures
    Figure 1. Neurofibromatosis Type 1 Product Picture
    Figure 3. Global Neurofibromatosis Type 1 Market Share by Type in 2021 & 2028
    Figure 3. 10 mg Product Picture
    Figure 4. 25 mg Product Picture
    Figure 5. Global Neurofibromatosis Type 1 Market Share by Application in 2021 & 2028
    Figure 6. Hospitals
    Figure 7. Clinics
    Figure 8. Others
    Figure 9. Neurofibromatosis Type 1 Report Years Considered
    Figure 10. Global Neurofibromatosis Type 1 Sales 2017-2028 (K Units)
    Figure 11. Global Neurofibromatosis Type 1 Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 12. Global Neurofibromatosis Type 1 Revenue 2017-2028 (US$ Million)
    Figure 13. Global Neurofibromatosis Type 1 Revenue Market Share by Region in Percentage: 2021 Versus 2028
    Figure 14. Global Neurofibromatosis Type 1 Sales Market Share by Region (2017-2022)
    Figure 15. Global Neurofibromatosis Type 1 Sales Market Share by Region (2023-2028)
    Figure 16. North America Neurofibromatosis Type 1 Sales YoY (2017-2028) & (K Units)
    Figure 17. North America Neurofibromatosis Type 1 Revenue YoY (2017-2028) & (US$ Million)
    Figure 18. Europe Neurofibromatosis Type 1 Sales YoY (2017-2028) & (K Units)
    Figure 19. Europe Neurofibromatosis Type 1 Revenue YoY (2017-2028) & (US$ Million)
    Figure 20. Asia-Pacific Neurofibromatosis Type 1 Sales YoY (2017-2028) & (K Units)
    Figure 21. Asia-Pacific Neurofibromatosis Type 1 Revenue YoY (2017-2028) & (US$ Million)
    Figure 22. Latin America Neurofibromatosis Type 1 Sales YoY (2017-2028) & (K Units)
    Figure 23. Latin America Neurofibromatosis Type 1 Revenue YoY (2017-2028) & (US$ Million)
    Figure 24. Middle East & Africa Neurofibromatosis Type 1 Sales YoY (2017-2028) & (K Units)
    Figure 25. Middle East & Africa Neurofibromatosis Type 1 Revenue YoY (2017-2028) & (US$ Million)
    Figure 26. The Neurofibromatosis Type 1 Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
    Figure 27. The Top 5 and 10 Largest Manufacturers of Neurofibromatosis Type 1 in the World: Market Share by Neurofibromatosis Type 1 Revenue in 2021
    Figure 28. Global Neurofibromatosis Type 1 Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
    Figure 29. Global Neurofibromatosis Type 1 Sales Market Share by Type (2017-2028)
    Figure 30. Global Neurofibromatosis Type 1 Revenue Market Share by Type (2017-2028)
    Figure 31. Global Neurofibromatosis Type 1 Sales Market Share by Application (2017-2028)
    Figure 32. Global Neurofibromatosis Type 1 Revenue Market Share by Application (2017-2028)
    Figure 33. North America Neurofibromatosis Type 1 Sales Market Share by Type (2017-2028)
    Figure 34. North America Neurofibromatosis Type 1 Revenue Market Share by Type (2017-2028)
    Figure 35. North America Neurofibromatosis Type 1 Sales Market Share by Application (2017-2028)
    Figure 36. North America Neurofibromatosis Type 1 Revenue Market Share by Application (2017-2028)
    Figure 37. North America Neurofibromatosis Type 1 Sales Share by Country (2017-2028)
    Figure 38. North America Neurofibromatosis Type 1 Revenue Share by Country (2017-2028)
    Figure 39. U.S. Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)
    Figure 40. Canada Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)
    Figure 41. Europe Neurofibromatosis Type 1 Sales Market Share by Type (2017-2028)
    Figure 42. Europe Neurofibromatosis Type 1 Revenue Market Share by Type (2017-2028)
    Figure 43. Europe Neurofibromatosis Type 1 Sales Market Share by Application (2017-2028)
    Figure 44. Europe Neurofibromatosis Type 1 Revenue Market Share by Application (2017-2028)
    Figure 45. Europe Neurofibromatosis Type 1 Sales Share by Country (2017-2028)
    Figure 46. Europe Neurofibromatosis Type 1 Revenue Share by Country (2017-2028)
    Figure 47. Germany Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)
    Figure 48. France Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)
    Figure 49. U.K. Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)
    Figure 50. Italy Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)
    Figure 51. Russia Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)
    Figure 52. Asia Pacific Neurofibromatosis Type 1 Sales Market Share by Type (2017-2028)
    Figure 53. Asia Pacific Neurofibromatosis Type 1 Revenue Market Share by Type (2017-2028)
    Figure 54. Asia Pacific Neurofibromatosis Type 1 Sales Market Share by Application (2017-2028)
    Figure 55. Asia Pacific Neurofibromatosis Type 1 Revenue Market Share by Application (2017-2028)
    Figure 56. Asia Pacific Neurofibromatosis Type 1 Sales Share by Region (2017-2028)
    Figure 57. Asia Pacific Neurofibromatosis Type 1 Revenue Share by Region (2017-2028)
    Figure 58. China Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)
    Figure 59. Japan Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)
    Figure 60. South Korea Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)
    Figure 61. India Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)
    Figure 62. Australia Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)
    Figure 63. Taiwan Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)
    Figure 64. Indonesia Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)
    Figure 65. Thailand Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)
    Figure 66. Malaysia Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)
    Figure 67. Philippines Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)
    Figure 68. Latin America Neurofibromatosis Type 1 Sales Market Share by Type (2017-2028)
    Figure 69. Latin America Neurofibromatosis Type 1 Revenue Market Share by Type (2017-2028)
    Figure 70. Latin America Neurofibromatosis Type 1 Sales Market Share by Application (2017-2028)
    Figure 71. Latin America Neurofibromatosis Type 1 Revenue Market Share by Application (2017-2028)
    Figure 72. Latin America Neurofibromatosis Type 1 Sales Share by Country (2017-2028)
    Figure 73. Latin America Neurofibromatosis Type 1 Revenue Share by Country (2017-2028)
    Figure 74. Mexico Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)
    Figure 75. Brazil Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)
    Figure 76. Argentina Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)
    Figure 77. Middle East and Africa Neurofibromatosis Type 1 Sales Market Share by Type (2017-2028)
    Figure 78. Middle East and Africa Neurofibromatosis Type 1 Revenue Market Share by Type (2017-2028)
    Figure 79. Middle East and Africa Neurofibromatosis Type 1 Sales Market Share by Application (2017-2028)
    Figure 80. Middle East and Africa Neurofibromatosis Type 1 Revenue Market Share by Application (2017-2028)
    Figure 81. Middle East and Africa Neurofibromatosis Type 1 Sales Share by Country (2017-2028)
    Figure 82. Middle East and Africa Neurofibromatosis Type 1 Revenue Share by Country (2017-2028)
    Figure 83. Turkey Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)
    Figure 84. Saudi Arabia Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)
    Figure 85. UAE Neurofibromatosis Type 1 Revenue (2017-2028) & (US$ Million)
    Figure 86. Neurofibromatosis Type 1 Value Chain
    Figure 87. Neurofibromatosis Type 1 Production Process
    Figure 88. Channels of Distribution
    Figure 89. Distributors Profiles
    Figure 90. Bottom-up and Top-down Approaches for This Report
    Figure 91. Data Triangulation
    Figure 92. Key Executives Interviewed
SELECT A FORMAT
Added to Cart

Electronic (PDF)
$4900
This license allows only one user to access the PDF.

Electronic (PDF)
$7350
This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Electronic (PDF)
$9800
This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Nano String

RELATED REPORTS

Global Krabbe Disease Treatment Market Insights Forecast to 2028
Global Krabbe Disease Treatment Market Insights, Forecast to 2028

120 Pages
Type: Report
Code: QYRE-Auto-28R1610
Mon Mar 14 00:00:00 UTC 2022

Add to Cart

Global Morquio Syndrome Treatment Market Insights Forecast to 2028
Global Morquio Syndrome Treatment Market Insights, Forecast to 2028

120 Pages
Type: Report
Code: QYRE-Auto-34H5635
Fri Mar 11 00:00:00 UTC 2022

Add to Cart

Global Leigh Syndrome Treatment Market Insights Forecast to 2028
Global Leigh Syndrome Treatment Market Insights, Forecast to 2028

120 Pages
Type: Report
Code: QYRE-Auto-35Y5644
Fri Mar 11 00:00:00 UTC 2022

Add to Cart

Global Mitochondrial Disorders Treatment Market Insights Forecast to 2028
Global Mitochondrial Disorders Treatment Market Insights, Forecast to 2028

120 Pages
Type: Report
Code: QYRE-Auto-19G5824
Fri Mar 11 00:00:00 UTC 2022

Add to Cart